Cover Story
CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.
By Tessa Vellek
In Brief
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - The Cancer Letter’s most-read stories of 2024
- Trump to dedicate $500M over 10 years to childhood cancer
- The unKOOL, unfiltered history of menthol cigarettes